Print Page     Close Window     

SEC Filings

424B3
BIOTIME INC filed this Form 424B3 on 02/04/2019
Entire Document
 

 

 

ASTERIAS BIOTHERAPEUTICS, INC.

CONDENSED BALANCE SHEETS

(IN THOUSANDS EXCEPT PAR VALUE AMOUNTS)

 

  

September 30,

2018

(Unaudited)

  

December 31,

2017

(Note 1)

 
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents  $6,424   $13,166 
Marketable equity securities   6,161    8,329 
Receivables   2,429    34 
Prepaid expenses and other current assets   748    1,187 
Total current assets   15,762    22,716 
           
NONCURRENT ASSETS          
Intangible assets, net   13,430    15,444 
Property, plant and equipment, net   598    4,543 
Other assets   24    389 
TOTAL ASSETS  $29,814   $43,092 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
CURRENT LIABILITIES          
Accounts payable and accrued expenses  $2,017   $2,958 
Deferred rent and lease incentives, current   402     
Capital lease liability, current   7    7 
Lease liability, current       556 
Total current liabilities   2,426    3,521 
           
NONCURRENT LIABILITIES          
Warrant liability   703    2,757 
Deferred revenue   1,000     
Capital lease liability, noncurrent   9    14 
Deferred rent and lease incentives, noncurrent   1,171    316 
Lease liability, noncurrent       2,941 
TOTAL LIABILITIES   5,309    9,549 
           
Commitments and contingencies (see Note 8)          
           
STOCKHOLDERS’ EQUITY          
Preferred Stock, $0.0001 par value, authorized 5,000 shares; none issued and outstanding        
Common Stock, $0.0001 par value, authorized 125,000 shares of Series A Common Stock and 75,000 shares of Series B Common Stock; 55,659 and 54,051 shares of Series A Common Stock issued and outstanding at September 30, 2018 and December 31, 2017, respectively; no shares of Series B Common Stock issued and outstanding at September 30, 2018 and December 31, 2017   6    5 
Additional paid-in capital   156,760    152,136 
Accumulated other comprehensive loss       (6,498)
Accumulated deficit   (132,261)   (112,100)
Total stockholders’ equity   24,505    33,543 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $29,814   $43,092 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 F-32 

© Copyright BioTime, Inc.